ES2150378B1 - Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. - Google Patents

Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.

Info

Publication number
ES2150378B1
ES2150378B1 ES009801708A ES9801708A ES2150378B1 ES 2150378 B1 ES2150378 B1 ES 2150378B1 ES 009801708 A ES009801708 A ES 009801708A ES 9801708 A ES9801708 A ES 9801708A ES 2150378 B1 ES2150378 B1 ES 2150378B1
Authority
ES
Spain
Prior art keywords
disorders
excess
derivatives
substance
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009801708A
Other languages
English (en)
Spanish (es)
Other versions
ES2150378A1 (es
Inventor
Ramon Merce-Vidal
Jordi Frigola-Constansa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Priority to ES009801708A priority Critical patent/ES2150378B1/es
Priority to CO99049291A priority patent/CO5080747A1/es
Priority to ARP990103870A priority patent/AR019999A1/es
Priority to NZ509645A priority patent/NZ509645A/xx
Priority to RU2001106644/15A priority patent/RU2223116C2/ru
Priority to JP2000563228A priority patent/JP2002522359A/ja
Priority to CZ2001412A priority patent/CZ292065B6/cs
Priority to DE69914085T priority patent/DE69914085T8/de
Priority to DK99940199T priority patent/DK1103243T3/da
Priority to TW088113353A priority patent/TW445259B/zh
Priority to PCT/ES1999/000255 priority patent/WO2000007542A2/es
Priority to TR2001/00378T priority patent/TR200100378T2/xx
Priority to AU54229/99A priority patent/AU754124B2/en
Priority to BR9912807-1A priority patent/BR9912807A/pt
Priority to PL99346221A priority patent/PL193802B1/pl
Priority to ES99940199T priority patent/ES2213380T3/es
Priority to HU0105428A priority patent/HUP0105428A3/hu
Priority to KR1020017001560A priority patent/KR100558506B1/ko
Priority to CA002339661A priority patent/CA2339661C/en
Priority to US09/762,079 priority patent/US6518295B1/en
Priority to AT99940199T priority patent/ATE257379T1/de
Priority to EP99940199A priority patent/EP1103243B1/en
Priority to CNB998109150A priority patent/CN1151789C/zh
Priority to PT99940199T priority patent/PT1103243E/pt
Publication of ES2150378A1 publication Critical patent/ES2150378A1/es
Priority to ZA200100867A priority patent/ZA200100867B/en
Priority to NO20010634A priority patent/NO20010634L/no
Priority to IL14129501A priority patent/IL141295A0/xx
Application granted granted Critical
Publication of ES2150378B1 publication Critical patent/ES2150378B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES009801708A 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. Expired - Fee Related ES2150378B1 (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
ARP990103870A AR019999A1 (es) 1998-08-07 1999-08-04 Empleo de derivados de aril(heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso desustancia p.
CO99049291A CO5080747A1 (es) 1998-08-07 1999-08-04 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p
CA002339661A CA2339661C (en) 1998-08-07 1999-08-05 Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p
JP2000563228A JP2002522359A (ja) 1998-08-07 1999-08-05 過剰のサブスタンスpによって仲介される障害の処置用医薬の製造におけるアリール(またはヘテロアリール)アゾリルカルビノール誘導体の使用
CZ2001412A CZ292065B6 (cs) 1998-08-07 1999-08-05 Použití derivátů aryl (nebo heteroaryl)azolylkarbinolů pro přípravu léčiv k léčení chorob zprostředkovaných přebytkem substance P
DE69914085T DE69914085T8 (de) 1998-08-07 1999-08-05 Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
DK99940199T DK1103243T3 (da) 1998-08-07 1999-08-05 Anvendelse af aryl(eller heteroaryl)azolylcarbinol-derivater til behandling af lidelser medieret af et overskud af substans P
TW088113353A TW445259B (en) 1998-08-07 1999-08-05 Use of derivatives of aryl (or heteroaryl) azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance P
PCT/ES1999/000255 WO2000007542A2 (es) 1998-08-07 1999-08-05 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p
TR2001/00378T TR200100378T2 (tr) 1998-08-07 1999-08-05 P-maddesi aşırısının aracılık ettiği hastalıkların tedavisindeki ilaç
AU54229/99A AU754124B2 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
BR9912807-1A BR9912807A (pt) 1998-08-07 1999-08-05 Uso de derivados de arila (ou heteroarila) azolilcarbinol na fabricação de medicamento para tratamento de distúrbios mediados por excesso de substância p
PL99346221A PL193802B1 (pl) 1998-08-07 1999-08-05 Zastosowanie pochodnych arylo (lub heteroarylo) azolilokarbinoli do wytwarzania leku do leczenia zaburzeń wywoływanych nadmiarem substancji P
NZ509645A NZ509645A (en) 1998-08-07 1999-08-05 Utilization of phenyl or thienyl subtituted imidazole or pyrazole carbinol derivatives for treating conditions mediated by an excess of substance P
HU0105428A HUP0105428A3 (en) 1998-08-07 1999-08-05 Utilization of aryl or heteroaryl-azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p
KR1020017001560A KR100558506B1 (ko) 1998-08-07 1999-08-05 과도한 물질 p에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도
RU2001106644/15A RU2223116C2 (ru) 1998-08-07 1999-08-05 Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
US09/762,079 US6518295B1 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
AT99940199T ATE257379T1 (de) 1998-08-07 1999-08-05 Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
EP99940199A EP1103243B1 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives for the treatment of troubles mediated by an excess of substance p
CNB998109150A CN1151789C (zh) 1998-08-07 1999-08-05 芳基(或杂芳基)吡咯基甲醇的衍生物的应用
PT99940199T PT1103243E (pt) 1998-08-07 1999-08-05 Utilizacao de derivados aril(ou heteroaril)azolilcarbinol na preparacao de um medicamento para o tratamento de problemas mediados por um excesso de substancia p
ES99940199T ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.
ZA200100867A ZA200100867B (en) 1998-08-07 2001-01-31 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P.
NO20010634A NO20010634L (no) 1998-08-07 2001-02-06 Anvendelse av derivater av aryl (eller heteroaryl)azolylkarbinol ved fremstilling av et medikament for behandling av forstyrrelser formidlet av et overskudd av substans P
IL14129501A IL141295A0 (en) 1998-08-07 2001-02-07 Use of derivatives of aryl (or heteroaryl) azolycarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.

Publications (2)

Publication Number Publication Date
ES2150378A1 ES2150378A1 (es) 2000-11-16
ES2150378B1 true ES2150378B1 (es) 2001-07-01

Family

ID=8304839

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801708A Expired - Fee Related ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
ES99940199T Expired - Lifetime ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99940199T Expired - Lifetime ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.

Country Status (26)

Country Link
US (1) US6518295B1 (cg-RX-API-DMAC7.html)
EP (1) EP1103243B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002522359A (cg-RX-API-DMAC7.html)
KR (1) KR100558506B1 (cg-RX-API-DMAC7.html)
CN (1) CN1151789C (cg-RX-API-DMAC7.html)
AR (1) AR019999A1 (cg-RX-API-DMAC7.html)
AT (1) ATE257379T1 (cg-RX-API-DMAC7.html)
AU (1) AU754124B2 (cg-RX-API-DMAC7.html)
BR (1) BR9912807A (cg-RX-API-DMAC7.html)
CA (1) CA2339661C (cg-RX-API-DMAC7.html)
CO (1) CO5080747A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ292065B6 (cg-RX-API-DMAC7.html)
DE (1) DE69914085T8 (cg-RX-API-DMAC7.html)
DK (1) DK1103243T3 (cg-RX-API-DMAC7.html)
ES (2) ES2150378B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0105428A3 (cg-RX-API-DMAC7.html)
IL (1) IL141295A0 (cg-RX-API-DMAC7.html)
NO (1) NO20010634L (cg-RX-API-DMAC7.html)
NZ (1) NZ509645A (cg-RX-API-DMAC7.html)
PL (1) PL193802B1 (cg-RX-API-DMAC7.html)
PT (1) PT1103243E (cg-RX-API-DMAC7.html)
RU (1) RU2223116C2 (cg-RX-API-DMAC7.html)
TR (1) TR200100378T2 (cg-RX-API-DMAC7.html)
TW (1) TW445259B (cg-RX-API-DMAC7.html)
WO (1) WO2000007542A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200100867B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
WO2006010627A1 (en) * 2004-07-30 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
CA2637312A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
MX2009003801A (es) 2006-10-19 2009-04-22 Hoffmann La Roche Aminometil-4-imidazoles.
BRPI0718054A2 (pt) 2006-11-02 2013-11-05 Hoffmann La Roche 2-imidazóis substituídos como moduladores de receptores associados à traços de aminas
AU2007321376A1 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
WO2008071574A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
CA2675221C (en) 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
CA2691082A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
BRPI0812833A2 (pt) 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Taar 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
CA2695331A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010123999A2 (en) * 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
FR2742147B1 (fr) * 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
ES2234039T3 (es) * 1996-12-02 2005-06-16 MERCK SHARP & DOHME LTD. Uso de antagonistas del receptor nk-1 para tratar trastornos de depresion mayor.
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders
EP0942735A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating schizophrenic disorders
WO1998024447A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
AU5422999A (en) 2000-02-28
HUP0105428A3 (en) 2003-01-28
CZ292065B6 (cs) 2003-07-16
CO5080747A1 (es) 2001-09-25
NZ509645A (en) 2003-01-31
IL141295A0 (en) 2002-12-01
WO2000007542A2 (es) 2000-02-17
TR200100378T2 (tr) 2001-06-21
DE69914085T2 (de) 2004-11-25
ES2213380T3 (es) 2004-08-16
ES2150378A1 (es) 2000-11-16
DE69914085T8 (de) 2005-04-21
ATE257379T1 (de) 2004-01-15
BR9912807A (pt) 2001-10-16
NO20010634D0 (no) 2001-02-06
RU2223116C2 (ru) 2004-02-10
AU754124B2 (en) 2002-11-07
PL193802B1 (pl) 2007-03-30
EP1103243B1 (en) 2004-01-07
CN1151789C (zh) 2004-06-02
KR20010079616A (ko) 2001-08-22
TW445259B (en) 2001-07-11
PL346221A1 (en) 2002-01-28
US6518295B1 (en) 2003-02-11
PT1103243E (pt) 2004-05-31
EP1103243A2 (en) 2001-05-30
WO2000007542A3 (es) 2000-05-11
CZ2001412A3 (cs) 2001-08-15
DE69914085D1 (de) 2004-02-12
ZA200100867B (en) 2001-08-16
CA2339661C (en) 2006-10-17
NO20010634L (no) 2001-04-06
CN1317966A (zh) 2001-10-17
JP2002522359A (ja) 2002-07-23
DK1103243T3 (da) 2004-05-03
CA2339661A1 (en) 2000-02-17
AR019999A1 (es) 2002-03-27
KR100558506B1 (ko) 2006-03-07
HUP0105428A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
ES2150378A1 (es) Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
PA8487601A1 (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer
ES2099282T3 (es) Derivados de beta-aminoacidos substituidos utiles como inhibidores de la agregacion de plaquetas.
ATE509929T1 (de) Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
UY26130A1 (es) Compuestos para tratar la obesidad
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
PT1586319E (pt) Inibidores de gsk-3
UY28150A1 (es) Agentes terapeuticos
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
DK1104758T3 (da) Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
YU84791A (sh) Biciklicni 1-aza-cikloalkalni
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
DE69802679D1 (de) Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
BR9802005A (pt) Derivado de pirazola tricìclico
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
AR035685A1 (es) Derivados de isoxazolina, sus prodrogas, composiciones farmaceuticas que comprenden dichos compuestos, procesos para preparar dichas composiciones, uso de dichos compuestos para la fabricacion de medicamentos, uso de dichas composiciones para la fabricacion de medicamentos, procesos para la preparac
PA8471801A1 (es) Derivados de higromicina a
AR013844A1 (es) Compuestos derivados de 3-oxo-pirido[1,2-a] bencimidazol-4-carboxamida sustituidos en posicion 5 con alquilo que contiene heteroatomo,- y composiciones farmaceuticas que los comprenden.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
WO2004018482A3 (en) C6- and c9-substituted chromeno[4, 3-c]isoxazoline derivatives and their use as anti-depressants

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20001116

Kind code of ref document: A1

Effective date: 20001116

FD2A Announcement of lapse in spain

Effective date: 20180807